First-Line Retlirafusp Alfa Plus Chemotherapy for Human Epidermal Growth Factor Receptor 2–Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized, Double-Blind, Phase III Study (RELIGHT)
Journal of Clinical Oncology · 2026
DOI: 10.1200/jco-25-02933 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2026. Verfasst von Zhi Peng und 29 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Gastrointestinal Oncology, Peking University Cance…. Hauptthemen laut MEDLINE: Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols, Esophageal Neoplasms, Esophagogastric Junction. Die Arbeit nennt 25 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE To evaluate retlirafusp alfa (an anti–PD-L1/transforming growth factor-β bispecific antibody) plus standard chemotherapy as first-line treatment for unresectable, locally advanced or metastatic, human epidermal growth factor receptor 2 (HER2)–negative gastric or gastroesophageal junction adenocarcinoma in the first-line setting. METHODS In this randomized, double-blind (RELIGHT), phase III study, 731 patients with previously untreated, unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma were randomly assigned (1:1) to receive retlirafusp alfa or placebo intravenously every 3 weeks plus capecitabine and oxaliplatin (CAPOX). The primary end point was overall survival (OS), assessed in patients with PD-L1 combined positive score (CPS) ≥5 and the intention-to-treat analysis set. RESULTS Retlirafusp alfa plus CAPOX significantly prolonged OS versus placebo plus CAPOX in both patients with PD-L1 CPS ≥5 (median, 16.8 vs 10.4 months; stratified hazard ratio [HR], 0.53 [95% CI, 0.40-0.68]; one-sided P < .0001) and the intention-to-treat analysis set (median, 15.8 vs 11.2 months; stratified HR, 0.66 [95% CI, 0.53-0.81]; one-sided P < .0001). Progression-free survival benefit was observed with retlirafusp alfa plus CAPOX versus placebo plus CAPOX in both patients with PD-L1 CPS ≥5 (median, 7.6 v 5.5 months; stratified HR, 0.52 [95% CI, 0.42 to 0.66]) and the intention-to-treat analysis set (median, 7.0 v 5.5 months; stratified HR, 0.57 [95% CI, 0.48 to 0.69]). Grade ≥3 treatment-related adverse events were generally comparable between patients treated with retlirafusp alfa plus CAPOX (62.6% [228 of 364]) and those treated with placebo plus CAPOX (59.0% [216 of 366]). CONCLUSION Retlirafusp alfa plus CAPOX represents a first-line treatment option for unresectable, locally advanced or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma. A key limitation is that chemotherapy alone served as the comparator, given that the study protocol was finalized before PD-1 inhibitor plus chemotherapy became the approved standard-of-care regimen in China.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
- Department of Gastroenterology, Henan Cancer Hospital, Zhengzhou, China.
- Department of Gastroenterology, Harbin Medical University Cancer Hospital, Harbin, China.
- Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.
- Third Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
- Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
ORCID-Profile: Zhi Peng, Jun Yao, Lin Xie, Jun Bai, Zhongtao Zhang, Jun Zhang, Yanhong Deng, Lin Shen
Zitieren
APA
Peng, Z., Wang, J., Zhang, Y., Li, H., Zhao, Q., Zhu, X., Wei, S., Chen, Y., Yang, W., Yao, J., Zhang, M., Xie, L., Zhang, X., Zhao, P., Hu, C., Zhang, J., Gu, K., Bai, J., Chen, Y., …, & Shen, L. (2026). First-Line Retlirafusp Alfa Plus Chemotherapy for Human Epidermal Growth Factor Receptor 2–Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized, Double-Blind, Phase III Study (RELIGHT). Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-02933
Vancouver
Peng Z, Wang J, Zhang Y, Li H, Zhao Q, Zhu X, et al. First-Line Retlirafusp Alfa Plus Chemotherapy for Human Epidermal Growth Factor Receptor 2–Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized, Double-Blind, Phase III Study (RELIGHT). Journal of Clinical Oncology. 2026. doi:10.1200/jco-25-02933
BibTeX
@article{Peng2026,
author = {Peng, Zhi and Wang, Jufeng and Zhang, Yanqiao and Li, Hongli and Zhao, Qun and Zhu, Xiaodong and Wei, Shaozhong and Chen, Yan and Yang, Wenhui and Yao, Jun and Zhang, Mingjun and Xie, Lin and Zhang, Xizhi and Zhao, Ping and Hu, Changlu and Zhang, Jingdong and Gu, Kangsheng and Bai, Jun and Chen, Yigui and Zhang, Zhongtao and Zhang, Jun and Wang, Junsheng and Niu, Zuoxing and Pan, Yueyin and Liu, Zhenyang and Deng, Yanhong and Wang, Zhigao and Wang, Wenliang and Han, Hongxia and Shen, Lin},
title = {First-Line Retlirafusp Alfa Plus Chemotherapy for Human Epidermal Growth Factor Receptor 2–Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized, Double-Blind, Phase III Study (RELIGHT)},
journal = {Journal of Clinical Oncology},
year = {2026},
doi = {10.1200/jco-25-02933}
}
EUVIMED